X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.
Lead Product(s): Anakinra
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Kineret
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chances of full recovery.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Kineret
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
Details:
In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Kineret
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hellenic Institute for the Study of Sepsis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).
Lead Product(s): Anakinra
Therapeutic Area: Rare Diseases and Disorders Product Name: Kineret
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.
Lead Product(s): Anakinra
Therapeutic Area: Genetic Disease Product Name: Kineret
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.
Lead Product(s): Anakinra
Therapeutic Area: Genetic Disease Product Name: Kineret
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
